Palvella Therapeutics to attend FDA drug repurposing workshop
Palvella Therapeutics will attend an FDA public workshop on drug repurposing on Aug. 5, 2026, in Washington, D.C.
Chief Scientific Officer Jeffrey Martini is scheduled to deliver public comments on evidence standards, policy barriers, and regulatory pathways for repurposed therapies.
PVLA•
